UroGen Pharma (URGN) News Today → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free URGN Stock Alerts $14.30 +0.04 (+0.28%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024businesswire.com - May 4 at 3:20 PMNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trialbusinesswire.com - May 4 at 11:50 AMUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024businesswire.com - May 3 at 8:00 AM125,226 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Cerity Partners LLCmarketbeat.com - April 20 at 5:24 AMBuy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentationsmarkets.businessinsider.com - April 18 at 12:39 PMUroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC Wainwrightmarketbeat.com - April 18 at 8:23 AMUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancersbusinesswire.com - April 17 at 12:02 PMUroGen's UGN-103 advances to Phase 3 for bladder cancerinvesting.com - April 16 at 10:43 PMUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancerbusinesswire.com - April 15 at 8:00 AMUroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last weekfinance.yahoo.com - April 14 at 1:17 PMUrogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy Ratingmarkets.businessinsider.com - April 4 at 3:29 PMUroGen Pharma (NASDAQ:URGN) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 4 at 8:50 AMUroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells $168,600.00 in Stockinsidertrades.com - March 22 at 6:30 AMMark Schoenberg Sells 12,000 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stockmarketbeat.com - March 20 at 7:50 PMUroGen Pharma Ltd. (NASDAQ:URGN) to Post Q1 2025 Earnings of ($0.73) Per Share, HC Wainwright Forecastsmarketbeat.com - March 19 at 7:14 AMUroGen: All Eyes On UGN-102seekingalpha.com - March 18 at 11:48 PMOppenheimer Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $34.00marketbeat.com - March 18 at 6:32 PMUroGen Pharma (NASDAQ:URGN) Rating Reiterated by HC Wainwrightmarketbeat.com - March 18 at 5:32 PMUroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 17 at 5:45 PMUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 15 at 2:14 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM)markets.businessinsider.com - March 14 at 11:32 PMUroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102finanznachrichten.de - March 14 at 6:32 PMUroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challengesfinance.yahoo.com - March 14 at 1:26 PMURGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 14 at 1:03 PMUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102finance.yahoo.com - March 14 at 8:25 AMUroGen Pharma earnings preview: what to expectmarkets.businessinsider.com - March 13 at 12:58 PMSchonfeld Strategic Advisors LLC Purchases Shares of 130,200 UroGen Pharma Ltd. (NASDAQ:URGN)marketbeat.com - March 9 at 5:42 AMUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 8 at 8:00 AMUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024finance.yahoo.com - March 4 at 9:33 AM3 Biotech Stocks Climbing the Ranks to Watchstocknews.com - March 1 at 12:11 PMUroGen falls as Teva seeks FDA nod for Jelmyto genericmsn.com - March 1 at 8:09 AMUroGen Pharma to Present at TD Cowen 44th Annual Health Care Conferencebusinesswire.com - February 26 at 8:00 AMURGN Mar 2024 22.500 callfinance.yahoo.com - February 19 at 12:50 AMSilverarc Capital Management LLC Buys Shares of 508,883 UroGen Pharma Ltd. (NASDAQ:URGN)marketbeat.com - February 18 at 12:53 PMURGN Mar 2024 17.500 callfinance.yahoo.com - February 17 at 3:49 PMURGN Mar 2024 10.000 putfinance.yahoo.com - February 17 at 3:49 PMJump Financial LLC Makes New $415,000 Investment in UroGen Pharma Ltd. (NASDAQ:URGN)marketbeat.com - February 12 at 4:35 AMUroGen Pharma Shares Insights at Guggenheim Healthcare Talksmsn.com - February 8 at 12:29 PMUroGen Pharma Ltd URGNmorningstar.com - February 6 at 11:40 PMUroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 3,789 Sharesmarketbeat.com - February 2 at 9:18 PMUroGen Pharma Ltd (URGN)investing.com - February 1 at 10:20 AMUroGen Pharma to Participate at Upcoming Investor Conferencesfinance.yahoo.com - February 1 at 10:20 AMClal Insurance Enterprises Holdings Ltd Has $3.11 Million Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)marketbeat.com - January 24 at 6:59 PMUroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102finance.yahoo.com - January 24 at 9:29 AMUroGen Pharma Signs With Medac To Develop Mitosin-based UGN-103 For Urothelial Cancersmarkets.businessinsider.com - January 17 at 12:57 PMUroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancersfinance.yahoo.com - January 17 at 12:57 PMShort Interest in UroGen Pharma Ltd. (NASDAQ:URGN) Rises By 15.6%marketbeat.com - January 14 at 10:57 AMUroGen Pharma to Participate in the B. Riley Healthcare Conferencefinance.yahoo.com - January 11 at 10:51 AMHarel Insurance Investments & Financial Services Ltd. Sells 155,373 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)marketbeat.com - January 11 at 10:24 AMShareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years agofinance.yahoo.com - November 27 at 9:35 AM Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. URGN Media Mentions By Week URGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.000.42▲Average Medical News Sentiment URGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼32▲URGN Articles Average Week Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Terns Pharmaceuticals News Today Rani Therapeutics News Today Precigen News Today Nkarta News Today Atai Life Sciences News Today Neoleukin Therapeutics News Today Atea Pharmaceuticals News Today Organogenesis News Today FibroBiologics News Today Erasca News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
